ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good day, and welcome to the ARS Pharmaceuticals Third Quarter ...
Business Insider15h
ARS Pharmaceuticals’ Strong Q3 2024 Highlights
Strategically, ARS Pharmaceuticals secured an exclusive license agreement with ALK-Abelló to commercialize neffy in Europe and other regions, which included an upfront payment of $145 million. In ...
Business Insider22h
Nuvalent’s Promising ALK and ROS1 Programs Drive Buy Rating Amid Strong Financial Position and Upcoming Trials
Andrew Berens has given his Buy rating due to a combination of factors, primarily centered around Nuvalent’s promising developments in their ALK and ROS1 programs ... focusing on stocks such as Agios ...